- Home
- TXNM vs OGN Comparison
TXNM vs OGN Comparison
Compare TXNM & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXNM
- OGN
- Stock Information
- Founded
- TXNM 1917
- OGN 1923
- Country
- TXNM United States
- OGN United States
- Employees
- TXNM N/A
- OGN N/A
- Industry
- TXNM
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- TXNM
- OGN Health Care
- Exchange
- TXNM NYSE
- OGN Nasdaq
- Market Cap
- TXNM 4.4B
- OGN 4.0B
- IPO Year
- TXNM N/A
- OGN N/A
- Fundamental
- Price
- TXNM $53.57
- OGN $14.51
- Analyst Decision
- TXNM Buy
- OGN Hold
- Analyst Count
- TXNM 7
- OGN 5
- Target Price
- TXNM $53.57
- OGN $20.80
- AVG Volume (30 Days)
- TXNM 1.4M
- OGN 4.1M
- Earning Date
- TXNM 04-29-2025
- OGN 05-01-2025
- Dividend Yield
- TXNM 3.04%
- OGN 7.72%
- EPS Growth
- TXNM 162.37
- OGN N/A
- EPS
- TXNM 2.67
- OGN 3.33
- Revenue
- TXNM $1,971,199,000.00
- OGN $6,403,000,000.00
- Revenue This Year
- TXNM $14.45
- OGN N/A
- Revenue Next Year
- TXNM $4.92
- OGN $1.52
- P/E Ratio
- TXNM $20.07
- OGN $4.36
- Revenue Growth
- TXNM 1.65
- OGN 2.23
- 52 Week Low
- TXNM $35.35
- OGN $13.87
- 52 Week High
- TXNM $55.50
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- TXNM 58.82
- OGN 40.58
- Support Level
- TXNM $53.56
- OGN $14.81
- Resistance Level
- TXNM $54.63
- OGN $14.81
- Average True Range (ATR)
- TXNM 1.43
- OGN 0.47
- MACD
- TXNM 0.04
- OGN -0.09
- Stochastic Oscillator
- TXNM 62.08
- OGN 11.44
About TXNM TXNM ENERGY INC
TXNM Energy Inc is a holding company that owns regulated utility companies providing energy to houses and businesses across Texas and New Mexico using its utilities.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.